Abstract
In recent years, many bronchoscopic techniques have been developed in chronic obstructive airway inflammatory diseases, including asthma, COPD and emphysema. The main techniques with available data from randomised controlled trials are: 1) bronchial thermoplasty in asthma; 2) valves, coils and thermal vapor ablation in emphysema; and 3) targeted lung denervation in COPD. The objectives of this article are to describe the levels of evidence for efficacy and safety, long-term follow-up results beyond 1 year, and current recommendations for clinical practice from international guidelines for each technique.
Abstract
Many therapeutic bronchoscopic techniques have been recently developed including bronchial thermoplasty in asthma, and valves, coils and thermal vapor ablation in emphysema, and targeted lung denervation in COPD https://bit.ly/2VhMsDI
Footnotes
Number 6 in the Series “Interventional pulmonology” Edited by David Feller-Kopman and Hervé Dutau
Provenance: Commissioned article, peer reviewed.
Previous articles in this series: No. 1: DeMaio A, Sterman D. Bronchoscopic intratumoral therapies for nonsmall cell lung cancer. Eur Respir Rev 2020; 29: 200028. No. 2: Chandrika S, Yarmus L. Recent developments in advanced diagnostic bronchoscopy. Eur Respir Rev 2020; 29: 190184. No. 3: Kniese CM, Musani AI. Bronchoscopic treatment of inoperable nonsmall cell lung cancer. Eur Respir Rev 2020; 29: 200035. No. 4: Rosell A, Stratakos G. Therapeutic bronchoscopy for central airway disease. Eur Respir Rev 2020; 29: 1900178. No. 5: Bedawi EO, Guinde J, Rahman NM, et al. Advances in pleural infection and malignancy. Eur Respir Rev 2021; 30: 200002.
Conflict of interest: J.M. Perotin has nothing to disclose.
Conflict of interest: M. Dewolf has nothing to disclose.
Conflict of interest: C. Launois has nothing to disclose.
Conflict of interest: V. Dormoy has nothing to disclose.
Conflict of interest: G. Deslee reports personal fees from BTG/PneumRx and Nuvaira, during the conduct of the study; personal fees from Chiesi, Boehringer Ingelheim, AstraZeneca and Novartis, outside the submitted work.
- Received January 31, 2020.
- Accepted June 15, 2020.
- Copyright ©ERS 2021.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
